Clinical trial · no report yet · Phase 2
SABR-COMET
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET)
- NCT01446744 ↗
- Unknown
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- 111 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 76 | |
| Podcasts | 18 | |
| YouTube | 17 |
The trial
ClinicalTrials.gov- Official title
- Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): A Randomized Phase II Trial
- Phase
- Phase 2
- Status
- Unknown
- Conditions
- Metastatic Tumors
- Interventions
- Stereotactic ablative radiotherapy; palliative radiotherapy
- Arms
- Standard arm · Active comparator
- Stereotactic arm · Experimental
- Enrollment
- 99
- Primary outcomes
- Overall Survival
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's with London Regional Cancer Program, Canada, VU University of Amsterdam
- Start
- Nov 2011
- Primary completion
- Jun 2026 (estimated)
- Results posted
- No
- Registry record
- NCT01446744 · updated Oct 5, 2023
Publications
linked from the registry- Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Schlijper R, Bauman GS, Laba J, Qu XM, Warner A, Senan S. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol. 2020 Sep 1;38(25):2830-2838. doi: 10.1200/JCO.20.00818. Epub 2020 Jun 2. PubMed 32484754
- Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Griffioen G, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Bauman GS, Warner A, Senan S. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019 May 18;393(10185):2051-2058. doi: 10.1016/S0140-6736(18)32487-5. Epub 2019 Apr 11. PubMed 30982687
- Palma DA, Haasbeek CJ, Rodrigues GB, Dahele M, Lock M, Yaremko B, Olson R, Liu M, Panarotto J, Griffioen GH, Gaede S, Slotman B, Senan S. Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial. BMC Cancer. 2012 Jul 23;12:305. doi: 10.1186/1471-2407-12-305. PubMed 22823994